ACMG 2025 | Foundation Corporate Partner Insights Session
Precision Medicine across Oncology, Renal Genetics, and Reproductive Health
Date: Wednesday, March 19th, 2025
Time: 12:15 PM - 1:15 PM PT
Location: Los Angeles Convention Center
Address: 1201 South Figueroa Street, Los Angeles, CA 90015
Room: 408 A | Lunch provided
In this session, we will explore:
- How data from molecular residual disease testing can enhance awareness of hereditary cancer testing
- The interaction between the genetic causes of kidney disease and targeted therapies
- How expansion of prenatal screening improves outcomes through early diagnosis and perinatal treatment options
Genomic testing has traditionally been used for diagnosis. In this session, attendees will learn how results can be used to identify patients who would benefit from further testing and to inform treatment options. Join Natera to learn how genetic testing can enable a personalized approach with the potential to improve outcomes.
We look forward to seeing you there! RSVP to let us know if you will be attending.
Moderator:
Sheetal Parmar, MS, CGC
SVP Medical Affairs, Natera Women's Health
Panelists:
John Williams III, MD
Director of Reproductive Genetics and Professor of Obstetrics and Gynecology at Cedars-Sinai Medical Center and the David Geffen School of Medicine at UCLA
A. Katya Brossart, MS, CGC
Manager of Genetics Education & Engagement
Organ Health, Natera
Eileen Hoffman, MS, CGC
Medical Science Liaison, Natera Oncology
13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com | Do Not Share My Personal Information | Privacy Policy